Cognition Therapeutics Inc (NASDAQ: CGTX) on Friday, soared 10.95% from the previous trading day, before settling in for the closing price of $0.45. Within the past 52 weeks, CGTX’s price has moved between $0.34 and $2.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 4.07%. With a float of $33.80 million, this company’s outstanding shares have now reached $40.13 million.
In an organization with 28 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 31.18%, operating margin of -15783.33%, and the pretax margin is -8355.38%.
Cognition Therapeutics Inc (CGTX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cognition Therapeutics Inc is 15.78%, while institutional ownership is 13.31%. The most recent insider transaction that took place on Mar 14 ’24, was worth 9,975. In this transaction CEO & President of this company bought 5,700 shares at a rate of $1.75, taking the stock ownership to the 291,345 shares.
Cognition Therapeutics Inc (CGTX) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.22 earnings per share (EPS) for the period topping the consensus outlook (set at -0.24) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.07% per share during the next fiscal year.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Cognition Therapeutics Inc (CGTX) is currently performing well based on its current performance indicators. A quick ratio of 3.07 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.35 million. That was inferior than the volume of 0.48 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 88.96%. Additionally, its Average True Range was 0.05.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 7.03%, which indicates a significant decrease from 81.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.79% in the past 14 days, which was lower than the 134.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5623, while its 200-day Moving Average is $1.5986. However, in the short run, Cognition Therapeutics Inc’s stock first resistance to watch stands at $0.5361. Second resistance stands at $0.5778. The third major resistance level sits at $0.6257. If the price goes on to break the first support level at $0.4465, it is likely to go to the next support level at $0.3986. The third support level lies at $0.3569 if the price breaches the second support level.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
Market capitalization of the company is 19.84 million based on 40,058K outstanding shares. Right now, sales total 0 K and income totals -25,790 K. The company made 0 K in profit during its latest quarter, and -7,040 K in sales during its previous quarter.
